Patents Examined by Patricia L. Morris
  • Patent number: 11420953
    Abstract: Novel co-crystal and eutectic crystal of kojic acid and a co-former that are excellent in physical properties are provided. In one aspect, novel co-crystals of kojic acid and a co-former that is maltol or ethyl maltol are provided. In another aspect, novel crystal of a eutectic mixture of kojic acid and a co-former that is selected from the group consisting of, maltol, ethyl maltol, methyl paraben and propyl gallate are provided. Methods for producing the novel co-crystal or eutectic crystal are also described. The novel co-crystals and eutectic crystals may be included in a pharmaceutical composition, a health food product or a medical food product for the treatment and/or prophylaxis of a neuropsychiatric disorder.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: August 23, 2022
    Assignee: SYNEURX INTERNATIONAL (TAIWAN) CORP.
    Inventors: Guo-Chuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 11370773
    Abstract: Disclosed are small molecule antagonists of human ?4?7 integrin, and methods of using them to treat a number of diseases and conditions.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: June 28, 2022
    Assignee: Morphic Therapeutic, Inc.
    Inventors: Matthew G. Bursavich, Dan Cui, James E. Dowling, Kristopher N. Hahn, Bryce A. Harrison, Fu-Yang Lin, Blaise S. Lippa, Bruce N. Rogers, Dawn M. Troast, Cheng Zhong, Kyle D. Konze, Aleksey I. Gerasyuto, Byungchan Kim, Salma Rafi, Tyler Day, Eugene Hickey, Evelyne Houang, Robert Zahler
  • Patent number: 11345695
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: May 31, 2022
    Assignee: Guangzhou Innocare Pharma Tech Co., Ltd.
    Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni, Mark Mulvihill
  • Patent number: 11339147
    Abstract: Disclosed is a compound as shown in formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, and the present invention relates to the use of same in the preparation of a drug for treating FXR-related diseases.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: May 24, 2022
    Assignee: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD.
    Inventors: Haiying He, Jun Yu, Shuhui Chen
  • Patent number: 11337964
    Abstract: Disclosed are a novel isoindoline derivative, a pharmaceutical composition and use thereof. The compound of formula I, or the pharmaceutically acceptable salt, solvate, polymorph, co-crystal, stereoisomer, isotopic compound, metabolite or prodrug thereof disclosed in the invention can regulate the generation and/or activity of PDE4 and/or TNF-? so as to effectively treat cancer and inflammatory diseases.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 24, 2022
    Assignee: Kangpu Biopharmaceuticals, Ltd.
    Inventors: Wen-Cherng Lee, Baisong Liao, Lei Zhang
  • Patent number: 11332465
    Abstract: The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: May 17, 2022
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Chunli Shen, Chengde Wu, Shenglin Chen, Shuhui Chen, Xiquan Zhang, Xin Tian
  • Patent number: 11312699
    Abstract: Provided herein are processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: April 26, 2022
    Assignee: Celgene Corporation
    Inventors: Marie G. Beauchamps, Gregg Feigelson, Jianxin Han, Joshua Hansen, Mohit A. Kothare, Michael James Williams, Michael J. Zacuto, Weihong Zhang
  • Patent number: 11312705
    Abstract: A heteroaryl[4,3-c]pyrimidin-5-amine derivative, a preparation method therefor, and medical uses thereof are provided. Specifically, a heteroaryl[4,3-c]pyrimidin-5-amine derivative of formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and uses thereof as therapeutic agents are provided. In particular, the provided compounds can be used as A2a receptor antagonists and for treatment of conditions or symptoms that are ameliorated by inhibiting the A2a receptor. The various substituent groups in the formula (I) have the meanings as described in the specification.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: April 26, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Biao Lu, Shenglan Wang, Xiaodong Shen, Feng He, Weikang Tao
  • Patent number: 11306061
    Abstract: Pure crystalline forms of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, and an amorphous form, pharmaceutical compositions thereof, and methods for making the same, are disclosed.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: April 19, 2022
    Assignees: Rezolute, Inc., ActiveSite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Chilcote, Julian Scott Northen, Jamie Marshall
  • Patent number: 11286249
    Abstract: The present invention provides compounds of the Formula wherein L is selected from the group consisting of —CH2NHCH2—, —CH2NH—, —NH—, —S—, —S(O)—, —S(O)2—, —O—, —OCH2—, —OCH2CH2O—, —NHSO2NH—, or a pharmaceutically acceptable salt thereof; a compound of the formula: processes for preparing the compounds and their salts, a pharmaceutical composition, and methods of treating patients in need of such treatment.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: March 29, 2022
    Assignee: Eli Lilly and Company
    Inventors: Celia Lafuente Blanco, Nuria Diaz Buezo, Jose Antonio Martinez Perez, Gema Consuelo Sanz Gil, Julian Priego Soler
  • Patent number: 11279696
    Abstract: The Present Invention relates to process for the preparation of 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one represented by the following structural formula-1.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 22, 2022
    Assignee: MSN LABORATORIES PRIVATE LIMITED
    Inventors: Thirumalai Rajan Srinivasan, Eswaraiah Sajja, Venkat Reddy Ghojala, Rajashekar Kommera
  • Patent number: 11279685
    Abstract: The present invention relates to a method of separating racemic nicotine of Formula (1-a) as a mixture of the (R)- and (S)-enantiomers into the enantiomerically pure (S)- and (R)-nicotine represented by Formula (1-b) and (1-c), by adding a mixture of the L- and the D-enantiomer of a O,O?-disubstituted tartaric acid, wherein the molar ratio of the L- to the D-enantiomer is from 80:20 to 95:5, and obtaining the (S)-nicotine of formula (1-b), or by adding O,O?-dibenzoyl-D-tartaric acid and obtaining the (R)-nicotine of formula (1-c).
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 22, 2022
    Assignees: SIEGFRIED AG, CONTRAF-NICOTEX-TOBACCO GMBH
    Inventors: Beat Theodor Weber, Ben Pan
  • Patent number: 11274091
    Abstract: The present invention relates to cyclopentane compounds of Formula (I), physical forms thereof, processes for their production and their use in medicine.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: March 15, 2022
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Xiaolin Zhang, Weitao Pan, Grigorios Nikitidis, Jenny Susanna Marika Lindhagen
  • Patent number: 11273153
    Abstract: The present invention relates to certain novel substituted thiophene compounds and the finding that they display useful efficacy in the inhibition of the p38? MAPK enzyme. This provides for use of the compounds in various treatment methodologies related to MAPK inhibition, including the treatment of inflammation.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: March 15, 2022
    Assignee: EverBrilliant Pharma Pty Ltd
    Inventors: Henry Krum, Peter Scammells, Bing Wang, Natalie Vinh, Jamie Simpson, David Chalmers
  • Patent number: 11267785
    Abstract: Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino}acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, [(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2-carbonyl]amino}acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibitors or for treating conditions wherein prolyl hydroxylase inhibition is desired.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: March 8, 2022
    Assignee: Akebia Therapeutics, Inc.
    Inventors: Christopher M. Lanthier, Boris Gorin, Jan Oudenes, Craig Edward Dixon, Alan Quigbo Lu, James Densmore Copp, John Michael Janusz
  • Patent number: 11261161
    Abstract: The present disclosure provides processes for the preparation of a compound of formula: which exhibits apoptosis signal-regulating kinase (“ASK1”) inhibitory activity and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis. The disclosure also provides compounds that are synthetic intermediates.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: March 1, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Brandon Heath Brown, Troy Evan Reynolds
  • Patent number: 11254675
    Abstract: The invention relates to process for the preparation of grapiprant and its intermediates thereof. The invention also relates to grapiprant having a purity 98% or more and compounds of Formula (A), (B), (C) and (D) in an amount of 0.5 or less, relative to grapiprant, by area percentage of HPLC. The invention also relates to an amorphous form of grapiprant and process for preparation thereof.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: February 22, 2022
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Kumar Kamlesh Singh, Jitendra Maganbhai Gajera, Sumer Singh Chundavat, Dipak Ambalal Patel
  • Patent number: 11254662
    Abstract: Halogenated analogs of 5-aza-2?-deoxycytidine, such as halogenated analogs of 5-aza-4?-thio-2?-deoxycytidine (5-aza-T-dCyd) are described. Pharmaceutical compositions including a halogenated analog and methods of using the halogenated analogs to inhibit neoplasia are described.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: February 22, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Joel Morris, Donn G. Wishka, Omar Diego Lopez
  • Patent number: 11247989
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: February 15, 2022
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • Patent number: 11247986
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 15, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu